Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Cara Therapeutics (GB:0HTC)
LSE:0HTC
Cara Therapeutics (0HTC) Share Price & Analysis
0 Followers
0HTC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.04 - $12.86
Previous Close$3.32
Volume115.00
Average Volume (3M)1.73K
Market Cap
$170.59M
Enterprise Value$200.21M
Total Cash (Recent Filing)$47.80M
Total Debt (Recent Filing)$77.42M
Price to Earnings (P/E)N/A
Beta0.95
Next Earnings
Aug 07, 2023EPS Estimate
-$0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,983,227
10 Day Avg. Volume211
30 Day Avg. Volume1,726
Standard Deviation0.16
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.27
Price to Sales (P/S)165.95
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.63
Enterprise Value/Gross Profit4.78
Enterprise Value/Ebitda-2.36
Forecast
1Y Price Target
$16.14Price Target Upside386.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Cara Therapeutics News
0HTC FAQ
What was Cara Therapeutics’s price range in the past 12 months?
Cara Therapeutics lowest share price was $3.04 and its highest was $12.86 in the past 12 months.
What is Cara Therapeutics’s market cap?
Currently, no data Available
When is Cara Therapeutics’s upcoming earnings report date?
Cara Therapeutics’s upcoming earnings report date is Aug 07, 2023 which is in 60 days.
How were Cara Therapeutics’s earnings last quarter?
Cara Therapeutics released its earnings results on May 15, 2023. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.513 by $0.023.
Is Cara Therapeutics overvalued?
According to Wall Street analysts Cara Therapeutics’s price is currently Undervalued.
Does Cara Therapeutics pay dividends?
Cara Therapeutics does not currently pay dividends.
What is Cara Therapeutics’s EPS estimate?
Cara Therapeutics’s EPS estimate is -$0.54.
How many shares outstanding does Cara Therapeutics have?
Currently, no data Available
What happened to Cara Therapeutics’s price movement after its last earnings report?
Cara Therapeutics reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.513. Following the earnings report the stock price went up 13.091%.
Which hedge fund is a major shareholder of Cara Therapeutics?
Among the largest hedge funds holding Cara Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Cara Therapeutics’s shares valued at 10M.
---
Cara Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.14 (386.44% Upside)
$16.14 (386.44% Upside)
Blogger Sentiment
Bullish
GB:0HTC Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.68%
12-Months-Change
Fundamentals
Return on Equity
-49.54%
Trailing 12-Months
Asset Growth
-31.53%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cara Therapeutics
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
---
Cara Therapeutics
―
BioCryst
―
Crispr Therapeutics AG
―
Fate Therapeutics
―
Gilead Sciences
―
---